Have a feature idea you'd love to see implemented?
Let us know!
ZLAB Zai Lab Ltd
Price (delayed)
$25.7
Market cap
$2.56B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.7
Enterprise value
$1.97B
Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To
Highlights
Zai Lab's revenue has increased by 35% YoY and by 10% from the previous quarter
ZLAB's gross profit is up by 31% year-on-year and by 11% since the previous quarter
The quick ratio has dropped by 61% year-on-year and by 15% since the previous quarter
The debt has soared by 50% from the previous quarter
Key stats
What are the main financial stats of ZLAB
Market
Valuations
Earnings
Shares outstanding
99.61M
Market cap
$2.56B
Enterprise value
$1.97B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.83
Price to sales (P/S)
7.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.54
Revenue
$355.75M
EBIT
-$269.5M
EBITDA
-$250.03M
Free cash flow
-$177.27M
Per share
Balance sheet
Liquidity
EPS
-$2.7
Free cash flow per share
-$1.81
Book value per share
$6.7
Revenue per share
$3.62
TBVPS
$9.48
Total assets
$985.35M
Total liabilities
$317.68M
Debt
$125.69M
Equity
$667.67M
Working capital
$574.23M
Debt to equity
0.19
Current ratio
3.01
Quick ratio
2.74
Net debt/EBITDA
2.36
Margins
Efficiency
Dividend
EBITDA margin
-70.3%
Gross margin
63.2%
Net margin
-76.1%
Operating margin
-92.1%
Return on assets
-27.1%
Return on equity
-37%
Return on invested capital
-465.8%
Return on capital employed
-38.6%
Return on sales
-75.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZLAB stock price
How has the Zai Lab stock price performed over time
Intraday
-2.02%
1 week
-3.64%
1 month
-8.21%
1 year
-6.27%
YTD
-5.96%
QTD
6.46%
Financial performance
How have Zai Lab's revenue and profit performed over time
Revenue
$355.75M
Gross profit
$224.74M
Operating income
-$327.57M
Net income
-$270.85M
Gross margin
63.2%
Net margin
-76.1%
Zai Lab's revenue has increased by 35% YoY and by 10% from the previous quarter
The net margin has grown by 33% YoY and by 18% from the previous quarter
ZLAB's gross profit is up by 31% year-on-year and by 11% since the previous quarter
The company's operating margin rose by 26% YoY and by 14% QoQ
Growth
What is Zai Lab's growth rate over time
Valuation
What is Zai Lab stock price valuation
P/E
N/A
P/B
3.83
P/S
7.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.54
The EPS has grown by 13% YoY and by 10% from the previous quarter
The stock's P/B is 32% above its last 4 quarters average of 2.9 but 26% below its 5-year quarterly average of 5.2
The equity has contracted by 24% YoY and by 5% from the previous quarter
ZLAB's price to sales (P/S) is 91% lower than its 5-year quarterly average of 75.9 but 4.3% higher than its last 4 quarters average of 6.8
Zai Lab's revenue has increased by 35% YoY and by 10% from the previous quarter
Efficiency
How efficient is Zai Lab business performance
Zai Lab's return on invested capital has shrunk by 106% YoY and by 25% QoQ
The ROS has grown by 34% YoY and by 18% from the previous quarter
ZLAB's ROE is down by 19% YoY but it is up by 2.6% QoQ
The ROA has grown by 8% from the previous quarter but it has contracted by 2.3% YoY
Dividends
What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZLAB.
Financial health
How did Zai Lab financials performed over time
The company's total liabilities has surged by 95% YoY and by 12% QoQ
The quick ratio has dropped by 61% year-on-year and by 15% since the previous quarter
The debt is 81% less than the equity
Zai Lab's debt to equity has soared by 58% from the previous quarter
The debt has soared by 50% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.